[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Atrial Fibrillation Network\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100622231",false,"NCT07380932","Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair","Inclusion Criteria:\n\n* Patients with documented atrial fibrillation (AF).\n* Transcatheter edge-to-edge mitral-valve repair (TEER) for severe functional mitral valve regurgitation (MR) with successful result (less than moderate MR, gradient \\\u003C 5 mmHg) performed within a period of minimum of 30 days and a maximum of 6 months. Moderate residual MR is eligible if no further mitral valve intervention or surgery is planned and patient is stable for \\> 3 months.\n* Provision of signed informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Patient not suitable for AF ablation\n* Previous ablation procedure for AF\n* Acute coronary syndrome, cardiac surgery, angioplasty, or cerebrovascular accident within 2 months prior to enrolment\n* Untreated hypothyroidism or hyperthyroidism requiring therapy\n* Enrolment in another randomised study\n* Indication for cardiac resynchronization therapy\n* Current pregnancy, breastfeeding, or women not using reliable contraceptive measures during fertility age\n* Mental or physical inability to participate in the study\n* Planned cardiovascular intervention or operation\n* Life expectancy ≤ 12 month","ALL","18 Years",{"count":17,"type":18},956,"ESTIMATED","INTERVENTIONAL",[21],"NA","CABA-MiTRA-AFNET12 is a non-commercial, parallel-group, prospective, randomised, open, blinded endpoint assessment (PROBE), multi-centre, therapy strategy trial. The trial investigates patients with severe mitral valve regurgitation who have undergone transcatheter edge-to-edge mitral valve repair (M-TEER) and have concomitant atrial fibrillation (AF). The objective is to assess whether catheter ablation of AF is superior to standard-of-care treatment in patients after TEER in reduction of major adverse cardiovascular and cerebrovascular events (MACCE).",[24,25],"Atrial Fibrillation (AF)","Mitral Valve (MV) Regurgitation",[27,28,29,30],"Atrial fibrillation","Mitral valve regurgitation","Mitral valve repair","Catheter ablation","NOT_YET_RECRUITING","2026-01-23",{"date":34,"type":35},"2026-02-02","ACTUAL",{"date":37,"type":18},"2026-07-01",{"date":39,"type":18},"2032-01-31",{"name":41,"class":42},"Atrial Fibrillation Network","OTHER",4,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":19,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100541002","NCT06324188","Early Atrial Fibrillation Ablation for Stroke Prevention in Patients With High Comorbidity Burden (EASThigh-AFNET 11)","Inclusion Criteria:\n\nI1. AF first diagnosed within 5 years prior to enrolment and documented in body surface ECG\n\nI2. High comorbidity estimated by CHA2DS2-VASc score of 4 or more\n\nI3. Patient suitable for ablation using cryoballoon ablation systems or other ablation systems with comparable efficacy and safety from Medtronic\n\nI4. Age ≥ 18 years\n\nI5. Provision of signed informed consent\n\nExclusion Criteria:\n\nGeneral exclusion criteria\n\nE1. Any disease that limits life expectancy to less than 1 year.\n\nE2. Participation in another clinical trial, either within the 3 months prior to enrolment or still on-going (participation in potential sub-studies connected to this trial is permitted).\n\nE3. Previous participation in EASThigh-AFNET 11.\n\nE4. Pregnant women.\n\nE5. Breastfeeding women.\n\nE6. Drug abuse or clinically manifest alcohol abuse.\n\nExclusion criteria related to a cardiac condition\n\nE7. Prior AF ablation or surgical therapy of AF.\n\nE8. Patients not suitable for AF ablation.\n\nE9. Patients with a history of stroke which occurred within 3 months prior to enrolment.\n\nE10. Valve disease requiring specific therapy.\n\nExclusion criteria based on laboratory abnormalities\n\nE11. Clinically manifested thyroid dysfunction requiring therapy.",{"count":50,"type":18},2312,[21],"EASThigh-AFNET 11 is an international, prospective, randomized, open, blinded endpoint assessment, multicenter trial (Treatment Strategy trial).\n\nThe objective of EASThigh-AFNET 11 is to investigate whether early atrial fibrillation ablation in patients with atrial fibrillation (AF) and a high comorbidity burden (CHA2DS2-VASc ≥4) reduces cardiovascular events (stroke, cardiovascular death, or heart failure events) compared to usual care.",[54],"Atrial Fibrillation",[56,57,58,59,60,61,62,63],"Early atrial fibrillation ablation","High comorbidity burden","CHA2DS2-VASc score","Early rhythm control","Stroke","Heart failure","Cardiovascular death","Cryoballoon","RECRUITING","2026-01-06",{"date":67,"type":35},"2026-01-08",{"date":69,"type":35},"2024-10-14",{"date":71,"type":18},"2030-05",{"name":41,"class":42},7,""]